Skip Navigation


CIT can broadcast your seminar, conference or meeting live to a world-wide audience over the Internet as a real-time streaming video. The event can be recorded and made available for viewers to watch at their convenience as an on-demand video or a downloadable podcast. CIT can also broadcast NIH-only or HHS-only content.

FDA-NCI Workshop on Therapeutic Cancer Vaccines

Loading video...

 
   
Air date: Tuesday, October 27, 2009, 8:00:00 AM
Time displayed is Eastern Time, Washington DC Local
Views: Total views: 59 * This only includes stats from October 2011 and forward.
Category: Conferences
Runtime: 07:51:06
Description: FDA and NCI are holding a public workshop intended to facilitate the development of safe and effective cancer vaccine by optimizing early phase clinical trials based on lessons learned from completed Phase III studies.

In this workshop, the role of randomized Phase II clinical trials and adaptive study designs will be discussed. Furthermore, the workshop will emphasize the importance of monitoring immune responses in early phase trials in order to optimize immunological therapies and incorporating pretreatment biomarkers in early phase clinical studies that could predict the effect of specific treatment for patients (predictive biomarkers) in order to identify a population likely to benefit.

For more information, visit
http://web.ncifcrf.gov/events/cancervaccine/default.asp
Debug: Show Debug
NLM Title: FDA-NCI Workshop on Therapeutic Cancer Vaccines [electronic resource] / FDA and NCI.
Author: FDA-NCI Workshop on Therapeutic Cancer Vaccines
National Cancer Institute (U.S.)
Publisher:
Abstract: (CIT): FDA and NCI are holding a public workshop intended to facilitate the development of safe and effective cancer vaccine by optimizing early phase clinical trials based on lessons learned from completed Phase III studies. In this workshop, the role of randomized Phase II clinical trials and adaptive study designs will be discussed. Furthermore, the workshop will emphasize the importance of monitoring immune responses in early phase trials in order to optimize immunological therapies and incorporating pretreatment biomarkers in early phase clinical studies that could predict the effect of specific treatment for patients (predictive biomarkers) in order to identify a population likely to benefit.
Subjects: Cancer Vaccines
Clinical Trials, Phase II as Topic
Neoplasms--therapy
Publication Types: Congresses
Webcasts
Download: To download this event, select one of the available bitrates:
[384k]    How to download a Videocast
NLM Classification: QZ 266
NLM ID: 101519006
CIT Live ID: 7907
Permanent link: https://videocast.nih.gov/launch.asp?15397